Navigation Links
China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
Date:12/31/2009

esults could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    For the Company:
     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:    +1-626-581-9098
     Email:  info@yongxinchina.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:    +1-561-245-5155
     Email:  matt.hayden@hcinternational.net
     Web: http://www.hcinternational.net

SOURCE China Yongxin Pharmaceuticals, Inc.

RELATED LINKS
http://www.yongxinchina.com

'/>"/>

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/28/2015)... Brooklyn, NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of ... with their quirky humor and excellent customer service. Images such as the Fonz in ... website to add some flavor to the humdrum spectroscopy field. , FireflySci is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting ... business problems, is pleased to announce their ranking as one of the top 5000 ... the fastest-growing private companies across the nation. , “It is truly an honor to ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... PRINCETON, N.J., March 3 BioWa, Inc. ... agreement with Genentech, Inc. providing,Genentech additional access ... development of select antibodies for potential therapeutic,applications ... "BioWa is pleased to extend this ...
... 29 For the first time,researchers at North ... whose halves are physically or chemically,different -- so-called ... an alternating electrical field is applied to liquid,surrounding ... published in the Feb. 8, 2008, edition,of Physical ...
... - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... on,endocrine therapy and oncology, today announced the ... Vice President, Administrative & Legal,Affairs and Corporate ... of,Vice President and Chief Financial Officer of ...
Cached Biology Technology:BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology 2'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 2008, Cambridge, UK Any way you slice it, ... , The planarian, a flatworm normally living in ... a single planarian cut into 200 pieces can generate ... is not merely a fascinating master of regeneration, but can ...
... Hosted by Weill Cornell Medical College, the Ansary Symposium ... of leading figures in the field, including internationally known ... and ethical issues in stem cell research. ... -, Thursday, September 18, 8:00 AM-1:30 PM ...
... release is available in French . , Researchers ... of the Jewish General Hospital along with colleagues at ... (OHRI) report a significant breakthrough in the use of viruses ... oncolytic virotherapy. Their results were published in the September early ...
Cached Biology News:Ansary Symposium on Stem Cell Research at Weill Cornell Medical College 2Viral 'magic bullet' targets cancer cells with help of new compound 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
Biology Products: